Botanix Pharmaceuticals Limited (ASX: BOT) today provided investors with an update on its suite of cannabis-derived clinical trials that target dermatological and antimicrobial conditions. In addition to this, the company has provided its roadmap, outlining how Botanix will be moving forward amid the COVID-19 crisis.
Click HERE to read the article on The Green Fund.
Botanix Pharmaceuticals has entered into a supply agreement with Purisys. Purisys has one of the industry’s longest track records and a wide range of offerings in the cannabinoid space. It currently produces all major cannabinoids relevant to pharmaceutical and consumer products. Since 2016, Purisys has also manufactured pharmaceutical-grade cannabidiol at commercial scale utilising a patented process.
Click HERE to read the article on The Market Herald.
Amid escalating concerns over antibiotic resistance, several big drug makers are creating a new $1 billion for-profit venture to acquire or invest in small antibiotic companies and their nascent products, according to two people familiar with the plans.
Click HERE to see the article on STAT.
Botanix Pharmaceuticals Limited (ASX:BOT)—a clinical stage cannabinoid company—has received firm commitments for a $40 million placement led by specialist US-based biotech investment funds and leading US institutional investors.
The $40 million in funding—which was offered at a price of $0.21 per fully paid ordinary share—will be used to support the company’s cannabinoid clinical development and research portfolio.
Click HERE to read the article on The Green Fund.
The quest for new antibiotics has led researchers to a surprising candidate: the marijuana compound CBD.
A new study finds that CBD, or cannabidiol, is “remarkably effective” at killing bacteria, at least in a test tube, the researchers in the new study said. The results showed that CBD had antibiotic effects against a number of so-called Gram-positive bacteria, including types of staph and strep bacteria, as well as strains that had become resistant to other antibiotic drugs.
Click HERE to read the article on LiveScience.
